Iksuda Therapeutics are leading the way in creating next generation of next generation Antibody Drug Conjugates (ADCs) for the treatment of difficult to treat solid tumours including ovarian, lung and breast cancers. Their bespoke UK headquarters at The Biosphere has been built with expansion of our capabilities and personnel in mind as they continue to build our technologies and drug portfolio.
By developing technology-based solutions to issues currently limiting clinical success with ADCs, Iksuda has been able to further develop its own portfolio of drug candidates demonstrating a significant improvement over current clinical approaches and specifically targeting solid tumours with high unmet need.
Being based in The Biosphere means they have access to key technical skills, innovation and opportunities fostered by being close to a major University. The region also has a growing biotech cluster and is central to its widely acknowledged manufacturing capabilities in both small molecule and biologics.